一对中国夫妇为了治疗患有罕见基因突变的女儿梅（化名），联系了上海著名的神经科学家仇子龙，希望能透过基因疗法改善她的发育迟缓问题。这对夫妇支付了八十六万美元，让仇子龙为梅进行这项全球首创的脑部基因疗法治疗。（关键数字：860,000）

然而，在接受这项量身定做的治疗不到一周后，这位六岁的女孩便因为严重的免疫反应引发致命血栓而离世。《科学》杂志与「撤稿观察」组织的联合调查指出，梅的家人指控仇子龙未告知治疗可能导致死亡的风险，也未透露先前动物实验中出现的安全隐患。（关键数字：less than a week）

这起悲剧引发了严重的伦理疑虑，因为这项高风险的实验性治疗被用于一种非致命性的疾病上。此外，外部机构与伦理委员会的监管不足，也对中国致力成为全球生技领导者的雄心造成打击，凸显了科学发展必须建立在公开、诚实和透明的基础上。

A Chinese couple, desperate to help their daughter Mei (a pseudonym) who suffered from a rare genetic mutation causing developmental delays, contacted prominent Shanghai neuroscientist Zilong Qiu for gene therapy. For $860,000, Qiu agreed to administer this world-first, brain-directed gene therapy treatment to Mei.

Tragically, less than a week after receiving the tailored treatment, the six-year-old girl died from a fatal blood clot triggered by a severe immune reaction. A joint investigation by Science magazine and Retraction Watch revealed that Mei's family accused Qiu of failing to disclose the risk of death or the safety issues flagged during earlier animal testing.

This tragedy raises serious ethical concerns, as a highly risky experimental treatment was used for a non-fatal condition. Furthermore, the lack of adequate oversight by regulatory authorities and ethical review boards deals a blow to China's ambitions of becoming a global biotech leader, highlighting that true scientific advancement must be rooted in openness, honesty, and transparency.